{"url_path":"/sec/juns/8-k/2026-06-05/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1679628/0001493152-26-027500-index.html","accession_number":"0001493152-26-027500","cik":"0001679628","ticker":"JUNS","issuer_name":"JUPITER NEUROSCIENCES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1679628/0001493152-26-027500-index.html","primary_entity_key":"0001679628","primary_entity_name":"JUPITER NEUROSCIENCES, INC."},"word_count":546,"has_tables":true,"body_markdown":"**Item\n5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of\nCertain Officers.**\n\n** **\n\n**(e)\nCompensatory Arrangements of Certain Officers**\n\n** **\n\nThe\nfollowing sets forth certain compensatory arrangements entered into, adopted or modified by Jupiter Neurosciences, Inc. (the “Company”)\nduring the period covered by this Current Report.\n\n** **\n\n**Alison\nSilva**\n\n \n\nOn\nJune 5, 2026, the Company entered into amendment No. 3 (the “Amendment”) to the employment agreement with Alison Silva,\ndated September 1, 2021, as amended. The Amendment appoints Ms. Silva as the Company’s Chief Operating Officer and President and\nincreases Ms. Silva’s base salary to $340,200 from $315,000. In connection with the Amendment, on June 2, 2026, the board\nof directors of the Company (the “Board”), based on the recommendation of the compensation committee of the Board (the “Compensation\nCommittee”), approved a one-time grant of options to purchase up to 600,000 shares of the Company’s common stock under the\nJupiter Neurosciences, Inc. 2025 Equity Incentive Plan (the “Plan”) to Ms. Silva with an exercise price equal to the closing\nprice of the Company’s common stock on the Nasdaq Capital Market on the date of grant to recognize her contributions to the Company.\nSuch option grant vests over three years commencing from September 2, 2026 in equal quarterly installments, subject to the recipient’s\ncontinued service with the Company through each applicable vesting date.\n\n \n\nThe\nforegoing summary of the Amendment does not purport to be complete and is subject to, and qualified in its entirety, by the full text\nof the Amendment, a copy of which is attached to this Current Report as Exhibit 10.1.\n\n \n\n**Director\nCompensation**\n\n \n\nOn\nJune 2, 2026, the Compensation Committee approved a grant of stock options to each of the Company’s independent non-employee directors\nto purchase up to 100,000 shares of the Company’s common stock under the Plan, with an exercise price per share equal to the closing\nprice of the Company’s common stock on the Nasdaq Capital Market on the date of grant. Such option grants vest over three years\ncommencing from September 2, 2026 in equal quarterly installments, subject to the recipient’s continued service with the Company\nthrough each applicable vesting date.\n\n \n\n**Discretionary\nBonus Options in Lieu of Cash and Long-Term Incentive Compensation**\n\n \n\nOn\nJune 2, 2026, the Board, based on the recommendation of the Compensation Committee, approved discretionary bonuses to the following executives\nin the form of stock options under the Plan in lieu of cash:\n\n \n\n**Executive**\n \n**Title**\n \n**Option\nGrant**\n\nChrister\nRosén\n \nChairman\nof Board, Chief Executive Officer and Director\n \n747,783\n\nAlison\nSilva\n \nChief\nOperating Officer and President\n \n427,304\n\nSaleem\nElmasri\n \nChief\nFinancial Officer\n \n325,565\n\nMarshall\nHayward, Ph.D.\n \nChief\nScientific Officer and Director\n \n259,231\n\nAlexander\nRosén\n \nChief\nAdministrative Officer\n \n341,843\n\n \n\nIn\naddition, the Board, based on the recommendation of the Compensation Committee, approved a one-time grant of options to purchase up\nto 200,000 shares of the Company’s common stock under the Plan to Mr. Elmasri with an exercise price equal to the closing\nprice of the Company’s common stock on the Nasdaq Capital Market on the date of grant to recognize his contributions to the\nCompany. Each such grant vests over three years commencing from September 2, 2026 in equal quarterly installments, subject to the\nrecipient’s continued service with the Company through each applicable vesting date."}